New Zealand · Delayed Price · Currency is NZD Rua Bioscience Earnings Call Transcripts
Fiscal Year 2026
-
FY 2026 customer revenue rose 71% to NZD 2.58m, while operating losses narrowed 7%. A major UK agreement creates growth potential, but funding inventory and working capital remains the key near-term challenge.
Fiscal Year 2025
-
The meeting highlighted strong revenue growth, reduced losses, and expansion into five markets, while emphasizing the need for a NZD 2 million capital raise and the sale of a manufacturing facility to support ongoing operations. All resolutions were supported, and the board remains focused on cost control and strategic growth.
Fiscal Year 2024
-
The meeting reviewed a year of strategic refocus, international expansion, and financial challenges, with significant sales growth in early FY25. Shareholders approved resolutions on auditor remuneration and new share issuance, while management addressed liquidity, market competitiveness, and future growth plans.